[HTML][HTML] Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
SC George, EJJ Samuel - Frontiers in Chemistry, 2023 - frontiersin.org
177Lu is a radioisotope that has become increasingly popular as a therapeutic agent for
treating various conditions, including neuroendocrine tumors and metastatic prostate …
treating various conditions, including neuroendocrine tumors and metastatic prostate …
[HTML][HTML] The contest between internal and external-beam dosimetry: the zeno's paradox of achilles and the tortoise
F Cicone, KS Gleisner, A Sarnelli, L Indovina, J Gear… - Physica Medica, 2023 - Elsevier
Radionuclide therapy, also called molecular radiotherapy (MRT), has come of age, with
several novel radiopharmaceuticals being approved for clinical use or under development in …
several novel radiopharmaceuticals being approved for clinical use or under development in …
[HTML][HTML] Biodosimetry, can it find its way to the nuclear medicine clinic?
J Bolcaen, N Combrink, K Spoormans… - Frontiers in Nuclear …, 2023 - frontiersin.org
Personalised dosimetry based on molecular imaging is a field that grew exponentially in the
last decade due to the increasing success of Radioligand Therapy (RLT). Despite advances …
last decade due to the increasing success of Radioligand Therapy (RLT). Despite advances …
Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [177Lu] Lu-PSMA-617 Therapy
D Hardiansyah, E Yousefzadeh-Nowshahr… - Journal of Nuclear …, 2024 - Soc Nuclear Med
The aim of this study was to investigate the accuracy of single-time-point (STP) renal
dosimetry imaging using SPECT/CT data, a nonlinear mixed-effects (NLME) model, and a …
dosimetry imaging using SPECT/CT data, a nonlinear mixed-effects (NLME) model, and a …
[HTML][HTML] Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic
CA Kunos, ME Martin, MF Georgiou, RA Kuker… - Cancers, 2024 - mdpi.com
Simple Summary Until recently, radiopharmaceuticals have been underutilized for the
curative or the palliative treatment of cancer. Advances in a development program with …
curative or the palliative treatment of cancer. Advances in a development program with …
[HTML][HTML] A single-institution experience with 177Lu RPT workflow improvements and qualifying the SPECT/CT imaging for dosimetry
SC George, R Tolakanahalli, S Aguirre, TP Kim… - Frontiers in …, 2024 - frontiersin.org
Background and purpose Implementing any radiopharmaceutical therapy (RPT) program
requires a comprehensive review of system readiness, appropriate workflows, and training …
requires a comprehensive review of system readiness, appropriate workflows, and training …
[HTML][HTML] Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
D Grob, BM Privé, CHJ Muselaers… - EJNMMI …, 2024 - ejnmmiphys.springeropen.com
Bone marrow toxicity in advanced prostate cancer patients who receive [177Lu] Lu-PSMA-
617 is a well-known concern. In early stage patients; eg low volume metastatic hormone …
617 is a well-known concern. In early stage patients; eg low volume metastatic hormone …
[HTML][HTML] Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
C Meyer, L Szidonya, C Winters, A Mench… - Frontiers in Nuclear …, 2023 - frontiersin.org
PSMA-targeted radiopharmaceutical therapy is an established treatment option for
metastatic castration-resistant prostate cancer (mCRPC). However, response rates and …
metastatic castration-resistant prostate cancer (mCRPC). However, response rates and …
Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
K Herrmann, K Rahbar, M Eiber, R Sparks… - Journal of Nuclear …, 2024 - Soc Nuclear Med
In the VISION trial,[177Lu] Lu-PSMA-617 (177Lu-PSMA-617) plus protocol-permitted
standard of care significantly improved overall survival and radiographic progression-free …
standard of care significantly improved overall survival and radiographic progression-free …
Uncertainty Analysis of Time-Integrated Activity Coefficient in Single-Time-Point Dosimetry Using Bayesian Fitting Method
AF Jundi, MD Naqiyyun, BB Patrianesha… - Nuclear Medicine and …, 2024 - Springer
Purpose Calculation of the uncertainty of the individual time-integrated activity coefficient
(TIACs) is desirable in molecular radiotherapy. However, the calculation of TIAC's …
(TIACs) is desirable in molecular radiotherapy. However, the calculation of TIAC's …